Symposium "The Diabetes and Cancer Link: Lessons learned and current topics"
The symposium is targeted at clinicians and researchers at all levels interested in the link between diabetes, related traits and cancer. Registration is mandatory.
Register no later than 4 September 2019 to gunilla [dot] hughes_wulkan [at] med [dot] lu [dot] se
Diabetes and cancer are common chronic diseases. In Europe alone, there are 55.4 million individuals living with diabetes, mainly type 2 diabetes; while there are an estimated 3.5 million new cancer cases per year. The two diseases co-occur more often than may be expected from their separate prevalence. The strength of the association between diabetes and cancer is different for different cancer types and it is still not fully explained. Several potential mechanisms have been proposed and considered, including shared causes (e.g. obesity), interaction between mechanisms of importance for both diseases (e.g. insulin resistance, hyperinsulinemia, low grade inflammation), reverse causation (i.e. cancer causing diabetes), effects of diabetes treatments (e.g. insulin) and epidemiological biases that may appear in routine registers. At the same time, the presence of diabetes often has an adverse effect on cancer treatment, making it important to consider both diseases together in clinical care.
Organisers and funders
The symposium is organised by the EASD Diabetes and Cancer Study Group (DCSG)/Diabetes and Cancer Research Consortium (DCRC), Andrew Renehan (Manchester University), and Isabel Drake (Lund University). The symposium is funded by Stiftelsen för bekämpande av cancer vid Malmö Allmänna Sjukhus (MAS Cancer) and the Strategic Research Area (SRA) EpiHealth.